(15046233), N. B., (15029895), N. P., (15046236), A. M. B., (5870894), A. C., (25460), A. H., (15046239), A. M. S., . . . (8827107), J. M. B. (2025). Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Dyfyniad Arddull Chicago(15046233), Nigel Bundred, et al. Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. 2025.
Dyfyniad MLA(15046233), Nigel Bundred, et al. Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. 2025.